Sökning: onr:"swepub:oai:DiVA.org:uu-170772" >
Ghrelin receptor ag...
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis
-
Ejskjaer, N (författare)
-
Vestergaard, E T (författare)
-
Hellström, Per M., 1954- (författare)
-
visa fler...
-
Gormsen, L C (författare)
-
Madsbad, S (författare)
-
Madsen, J L (författare)
-
Jensen, T A (författare)
-
Pezzullo, J C (författare)
-
Christiansen, J S (författare)
-
Shaughnessy, L (författare)
-
Kosutic, G (författare)
-
visa färre...
- Wiley, 2009
- 2009
- Engelska.
-
Ingår i: Alimentary Pharmacology and Therapeutics. - : Wiley. - 0269-2813 .- 1365-2036. ; 29:11, s. 1179-1187
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: TZP-101 is a synthetic, selective ghrelin agonist in development for gastroparesis. AIM: To assess safety and effects of TZP-101 in diabetes patients with symptomatic gastroparesis. METHODS: Adults with type 1 or type 2 diabetes mellitus received placebo and TZP-101 (80, 160, 320 or 600 microg/kg) infusions in a cross-over manner following a radiolabelled meal. Blood glucose levels were stabilized using a hyperinsulinemic-euglycemic clamp. Primary endpoints were gastric half emptying and latency times. Secondary measures included assessment of gastroparesis symptoms and endocrine responses. RESULTS: Ten patients with type 1 (n = 7) or 2 (n = 3) diabetes, moderate-to-severe gastroparesis symptoms and > or =29% retention 4 h after a radiolabelled solid meal were enrolled. TZP-101 produced significant reductions in solid meal half-emptying (20%, P = 0.043) and latency (34%, P = 0.037) times vs. placebo. Reductions in overall postmeal symptom intensity (24%) and postprandial fullness (37%) following TZP-101 infusion were not statistically significant. Most adverse events were mild and self-limiting and there were no identifiable differences in numbers or types of adverse events between TZP-101 and placebo. CONCLUSIONS: This proof-of-concept study demonstrates that the ghrelin agonist TZP-101 is well-tolerated in diabetes patients with moderate-to-severe chronic gastroparesis and shows statistically significant improvements in gastric emptying.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- Gastroenterologi
- Gut hormones
- Medical Science
- Medicinsk vetenskap
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ejskjaer, N
-
Vestergaard, E T
-
Hellström, Per M ...
-
Gormsen, L C
-
Madsbad, S
-
Madsen, J L
-
visa fler...
-
Jensen, T A
-
Pezzullo, J C
-
Christiansen, J ...
-
Shaughnessy, L
-
Kosutic, G
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Alimentary Pharm ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet